Featured Research

from universities, journals, and other organizations

Staurosporine safely delivered in liposomes

Date:
October 21, 2013
Source:
University of California, San Diego Health Sciences
Summary:
Researchers have discovered a way to effectively deliver staurosporine (STS), a powerful anti-cancer compound that has vexed researchers for more than 30 years due to its instability in the blood and toxic nature in both healthy and cancerous cells.

Researchers at the University of California, San Diego School of Medicine have discovered a way to effectively deliver staurosporine (STS), a powerful anti-cancer compound that has vexed researchers for more than 30 years due to its instability in the blood and toxic nature in both healthy and cancerous cells. For the first time, the new method safely delivered STS to mouse tumors, suppressing them with no apparent side effects. The results were published online, October 20, in the International Journal of Nanomedicine.

"By itself, staurosporine shows potent activity against a number of cancer cell lines, including chemotherapy-resistant tumors. However, it also harms normal tissue," said senior author Santosh Kesari, MD, PhD, director of neuro-oncology at UC San Diego Moores Cancer Center. "With this study, we have been able to overcome the pharmacokinetic barriers to delivering staurosporine to tumors with the use of liposomes."

STS was originally isolated from the bacterium Streptomyces staurosporeus in 1977. The compound prompts a wide variety of cancer cell types to self-destruct, a process called apoptosis or programmed cell death. In its free form, STS is quickly metabolized and harmful to healthy cells. By trapping STS in tiny spheres called liposomes, Moores Cancer Center researchers have been able to effectively deliver the compound, past healthy tissue, to the tumor, with potent results.

Liposomes are microscopic bubbles made from the same molecules as cell membranes. Researchers use these hollow spheres to deliver therapeutic agents. Anti-cancer drugs can be loaded inside, while disguising agents coat the external membrane surface to hide the cancer-killer from the immune system.

"Staurosporine is able to drive virtually any mammal cell into apoptosis. It is able to uniquely interfere with several cell signaling pathways, even in cancer cell lines that defy frontline chemotherapy agents," said Milan Makale, PhD, a project scientist at UC San Diego Moores Cancer Center. "In the case of treatment-resistant brain, colon or pancreatic cancers, the potency of staurosporine stacks the odds in our favor of improving current treatments and outcomes. With an appropriately engineered liposomal delivery system, we can finally keep the drug in the blood longer, get it into the tumor better, and to a significant degree, spare healthy tissue."

In addition to encapsulating STS in a liposomal delivery system, the researchers developed a technique to increase the efficiency of drug-loading to more than 70 percent, the highest reported for a STS compound.

Drug-loading is the ratio of drug encapsulated by the liposome to the total amount of drug introduced into solution containing liposomes. The boosted loading was achieved by manipulating the pH environment of the cells with a proprietary method developed at Moores Cancer Center to force more STS into the liposomes. This platform technology is currently in the process of being licensed to a biotech company to develop it further for human use.

The effects of the delivery approach were validated with the use of fluorescence to track the STS penetration. The absence of weight loss in the mice confirmed the reduced toxicity.


Story Source:

The above story is based on materials provided by University of California, San Diego Health Sciences. Note: Materials may be edited for content and length.


Journal Reference:

  1. Milan Makale, Rajesh Mukthavaram, Pengfei Jiang, Rohit Saklecha, Dmitri Simberg, Ila Sri Bharati, Natsuko Nomura, Ying Chao, Sandra Pastorino, Sandeep C. Pingle, Valentina Fogal, Wolf Wrasidlo, Santosh Kesari. High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile. International Journal of Nanomedicine, 2013; 3991 DOI: 10.2147/IJN.S51949

Cite This Page:

University of California, San Diego Health Sciences. "Staurosporine safely delivered in liposomes." ScienceDaily. ScienceDaily, 21 October 2013. <www.sciencedaily.com/releases/2013/10/131021143310.htm>.
University of California, San Diego Health Sciences. (2013, October 21). Staurosporine safely delivered in liposomes. ScienceDaily. Retrieved September 3, 2014 from www.sciencedaily.com/releases/2013/10/131021143310.htm
University of California, San Diego Health Sciences. "Staurosporine safely delivered in liposomes." ScienceDaily. www.sciencedaily.com/releases/2013/10/131021143310.htm (accessed September 3, 2014).

Share This



More Health & Medicine News

Wednesday, September 3, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Doctors Fear They're Losing Battle Against Ebola

Doctors Fear They're Losing Battle Against Ebola

AP (Sep. 2, 2014) As a third American missionary is confirmed to have contracted Ebola in Liberia, doctors on the ground in West Africa fear they're losing the battle against the outbreak. (Sept. 2) Video provided by AP
Powered by NewsLook.com
Tech Giants Bet on 3D Headsets for Gaming, Healthcare

Tech Giants Bet on 3D Headsets for Gaming, Healthcare

AFP (Sep. 2, 2014) When Facebook acquired the virtual reality hardware developer Oculus VR in March for $2 billion, CEO Mark Zuckerberg hailed the firm's technology as "a new communication platform." Duration: 02:24 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins